Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (August 2022)
91 slides from Coloplast A/s Class B's roadshow presentation, August 2022
Slide 1: Roadshow presentation 9M 2021/22 - Making life easier
Roadshow presentation 9M 2021/22 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q3 with 8% organic growth and EBIT margin of 30%
Solid Q3 with 8% organic growth and an EBIT margin1 of 30%. FY 2021/22 financial guidance is unchanged REVENUE GROWTH Q3 2021/22 highlights Reported revenue (mDKK) Organic growth Reported growth • Organic growth of 8% and reported growth in DKK of 21%. Atos Medical contributed 9%- points to reported
Slide 4: Q3 organic growth of 8% driven mostly by Chronic Care
Q3 organic growth of 8% was driven mostly by Chronic Care, with solid contribution from all regions, excluding China Q3 2021/22 revenue by business area Q3 2021/22 revenue by geography Business Reported revenue Q3 Organic growth Share of organic Geographic Reported revenue Q3 Organic growth Share of
Slide 5: Q3 organic growth in Ostomy Care of 10%
Q3 organic growth in Ostomy Care of 10%, driven by Europe, the US and broad-based growth in Emerging markets excluding China Ostomy Care performance Q3 2021/22 highlights • Q3 organic growth was 10% and reported growth was 13% 13 • All regions contributed to growth, driven by Europe, the US and broa
Slide 6: Continence Care organic growth in Q3 was 5%
Continence Care organic growth in Q3 was 5%, negatively impacted by backorders in Collecting Devices Continence Care performance Q3 2021/22 highlights • Q3 organic growth was 5% and reported growth was 9% • All regions contributed to growth, led by Europe. Growth was negatively impacted by backorder
Slide 7: Interventional Urology grew 11% organically in Q3
Interventional Urology grew 11% organically in Q3; growth was broad-based Interventional Urology performance Q3 2021/22 highlights • Q3 organic growth was 11% and reported growth was 19% 82 • The Endourology portfolio was the main growth contributor, driven by Europe, the US and some tender phasing
Slide 8: Wound & Skin Care organic growth of 5% in Q3
Wound & Skin Care organic growth of 5% in Q3, driven by Compeed contract manufacturing and solid momentum in Europe Wound & Skin Care performance Q3 2021/22 highlights • Q3 organic growth was 5%, and reported growth was 10% 20 • Wound Care in isolation grew 4% organically in Q3, and 7% in 9M 2021/22
Slide 9: Voice & Respiratory Care contributed 9%-points to reported growth
Voice & Respiratory Care contributed 9%-points to reported growth in Q3, with double-digit underlying growth in the quarter Voice & Respiratory Care performance Q3 2021/22 highlights • The Atos Medical acquisition was completed on 31 January 2022, adding a new chronic care segment, Voice & Respirato
Slide 10: Q3 reported growth up 21%
Q3 reported growth was up 21%, with ~9%-points contribution from the Atos Medical acquisition and ~4%-points impact from currencies Revenue development (DKKm) Q3 2021/22 highlights • Reported revenue increased by DKK 1,014 million, or 21% vs. Q3 last year • Q3 organic growth was 8% or DKK 364 millio
Slide 11: Reported EBIT margin of 30% in Q3
Reported EBIT margin1 of 30% in Q3, reflecting an increased level of commercial activity and amortisation costs related to Atos Medical EBIT margin development before special items (%) Q3 2021/22 highlights • Q3 gross margin was 69%, on par with Q3 last year • Positive impact from: operating leverag
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings, impacted by the Atos Medical acquisition FCF development Comments Q3 2021/22 highlights • Free cash flow was an outflow of DKK 8,399 million compared to an inflow of DKK 1,626 million in 9M 2020/21 98 99 98 93 • The decrease was mainly driven b
Slide 13: FY 2021/22 guidance
FY 2021/22 guidance: Organic growth of 6-7% and reported EBIT margin before special items around 31% GUIDANCE 2021/22 GUIDANCE (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalised
Slide 14: Introduction to Coloplast
Making it easier Stina to be yourself LEADING INTIMATE HEALTHCARE Introduction to Coloplast
Slide 15: Coloplast has five business areas with global sales presence
Coloplast has five* business areas all with global sales presence Group revenue 2020/21 by segment Group revenue 2020/21 by geography 1 Continence Care European 1 36% markets 58% Ostomy Care Other developed 40% markets DKK DKK 25% 19.4bn 19.4bn 4 5 Interventional Urology Emerging Wound & Skin Care 1
Slide 16: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs WHO ARE OUR TYPICAL USERS HOW DO WE HELP THEM? People who have had their intestine redirected to an SenSura® Mio Ostomy Care opening in the abdominal wall Ostomy bag People in need of bladder or bowel management SpeediCath® Flex Continence Flexible
Slide 17: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 18: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 19: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Interventional Wound Voice & Respiratory Emerging Care Care Urology Care Care (Laryngectomy) Addressable market 18 - 19bn 14 - 15bn 12 - 13bn 22 - 24bn 1 – 1.5bn Siz
Slide 20: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future MACRO TRENDS IMPACT COMMERCIAL MODEL Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Payer preferen
Slide 21: Strive25 strategy will drive long-term value creation
Our Strive25 strategy will drive continued long-term value creation through revenue and earnings growth Voice & Chronic Care Respiratory Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainabilit
Slide 22: Strive25 sustainability priorities
With Strive25 Supporting we put emphasis sustainable on improving development our environmental with a strong emphasis on performance, improving our while continuingperformance environmental our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 pri
Slide 23: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas Economics & We expect to invest up to 2% Innovation of revenue in incremental OPEX investments Government Market Chronic Care Attractiveness I
Slide 24: Actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic screening based Portfolio Channel Early stage Large plays expansion & expansion technologies adjacencies Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voi
Slide 25: Key enablers to support the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses COMMERCIAL MODEL KEY ENABLERS Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Payer prefe
Slide 26: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence Control and continuity of 1 product supply ~30% MS ~15% MS ~5% MS +30 countries 2 Target the full value p
Slide 27: Clinical Performance Program to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? of users describe UTIs are their 45 %* 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 28: Progress across the Clinical Performance Program
We continue to make significant progress across the Clinical Performance Program Status August 2022 Expected launch Digital ostomy CE mark has been granted ✓ Product launch expected in the solution first half of Payer pilot studies in Germany and the UK initiated at the end of 2021 and progressing a
Slide 29: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, %* Cost item Development, in % of revenue* -0.5%-points 28.7 29.0 28.7 28.2 29.8 28-30 Distribution +1.2%-points 67.3 67.7 68.0 68.5 68.8 ~68 -0.1%-point 4.
Slide 30: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 9% ~800 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 21
Slide 31: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / accounting Master Data Labelling (Chronic
Slide 32: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and >30% R&D costs especially dri
Slide 33: Continued strong free cash flow during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 6% 4% 4% 4% 4% 5% 4% 26% 4% 4% 4% 23% 23% 23% 23
Slide 34: Attractive cash returns despite investments
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical acquisition Coloplast cash distribution to investors Highlights Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liqui
Slide 35: Stable shareholder returns through organic growth and margin
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 31% • Stable market trends in our Chronic Care business 10% 7% • Strong Coloplast Care retention program 9% and innovative DtC activities 06/07 08/09 10/1
Slide 36: Introduction to Atos Medical
Introduction to Atos Medical Stina the global market leader in laryngectomy
Slide 37: Atos Medical is the global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Atos key business highlights Atos financial development, SEKbn 2017-2020 revenue and EBITDA margin are reported Atos numbers2 2.2 SEKbn 2020 pro-forma Revenues1 2020 PF is calculated by Coloplast
Slide 38: Atos improves lives of patients following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective surgery After surgery, a Voice Prosthesis (VP) is inserted by a performed in the advanced stages of cancer healthcare professional, and the patient applies the Heat- and Moisture Exchan
Slide 39: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical procedure that The Tracheostomy patient journey starts with a cannula creates an opening in the neck for direct access insertion, which can be reversed at a
Slide 40: Untapped market potential from white space
Significant untapped market potential from “white space”, i.e. low treatment penetration and consumption Key facts Global Laryngectomy market potential1 (DKKbn) • 50,000 new total laryngectomy surgeries performed annually ILLUSTRATIVE • Only ~1/3 of patients undergoing TL surgery are treated with pr
Slide 41: Atos Medical guidance confirmed
Atos Medical guidance is confirmed, and expected to contribute to Coloplast Strive25 ambition Outlook Atos Medical is expected Organic revenue to contribute to Coloplast’s 8-10% growth Strive25 long-term financial guidance 7-9% organic growth EBITDA margin Mid-30s +30% EBIT margin Coloplast Group -
Slide 42: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with full Syner
Slide 43: Appendices
Tabitha Leading intimate healthcare LEADING INTIMATE HEALTHCARE Appendices
Slide 44: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Coloplast share listed on Nasdaq Copenhagen since 1983 Share Capital Ownership ~175.9 billion DKK (~24 billion USD) market cap @ ~828.6 DKK 11% per share (incl. A shares) 5% 1% Two share classes: 45% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote
Slide 45: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is 2.6x returned to shareholders through a 2.0x combination of dividends and share buy- backs 19,741 • Interest bearing debt will only be raised in connection with a major acquisition, such as 1.0x 0.2x 0.
Slide 46: 9M organic growth of 7% driven by Chronic Care
9M organic growth of 7% was driven by solid growth in the Chronic Care business across all regions, ex. China 9M 2021/22 revenue by business area 9M 2021/22 revenue by geography Business Reported revenue 9M Organic growth Share of organic Geographic Reported revenue 9M Organic growth Share of organi
Slide 47: 9M reported growth up 15%
9M reported growth was up 15%, with ~5%-points positive impact from the Atos acquisition and ~3%-points impact from currencies Revenue development (DKKm) 9M 2021/22 highlights • Reported revenue increased by DKK 2,194 million, or 15% vs. last year • 9M organic growth was 7% or DKK 972 million, drive
Slide 48: Reported EBIT margin of 31% in 9M
Reported EBIT margin1 of 31% in 9M reflecting increased level of commercial activity and the Atos Medical acquisition EBIT margin development before special items (%) 9M 2021/22 highlights • 9M gross margin was 69%, against 68% in 9M last year • Positive impact from operating leverage and the Atos M
Slide 49: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 32.7 36.3 36.2 36.8 31.9 32.3 34.7 34.6 34.9 31.2 32.0 31.5 28.7 29.0 28.1 28.7 28.2 29.8 25.2 25.8 23.4 23.6 23.4 23.7 4.0 4.0 4.2 4.1 3.9 4.4 4.4 5.0 5.2 4.4 4.1 3.5 3.7 3.9 3.9 3.8 3.9 3.9 16/17 17/18 18/19 19/20 20/21 YTD 21/22 16/17
Slide 50: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care 9 8 6 6 10 19 6 7 7 13 5 4 10 14 13 7,841 6 8 5%-p 7,1668 7,538 10 6,643 9 6,367 7 Contribution 5 6 to reported -7 growth 1,740 1,970 1,835 2,097 1,782 NA NA NA NA 757 17/18 18/19 19/20 20/21 Y
Slide 51: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 6 4 14 16 2 5 6 17 11 2 4 6 11 8 4 5 10,573 10,820 11,261 6 9,941 9,536 3 5 3,791 4,380 4,644 4,785 4,112 17/18 18/19 19/20 20/21 YTD 21/22 17/18 18/19 19/20 20/21 YTD 21/22 YTD reported growth rate includes 7%-p i
Slide 52: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Voice & Respiratory Care Ostomy and Continence Care • Voice & Respiratory Care 59 57 59 59 59 is Coloplast’s new business 2,330 2,357 2,397 area, added with the 2,156 2,225 acquisitio
Slide 53: 9M 2021/22 Atos Medical impact on EBIT
9M 2021/22 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 35% 32% 3% 31% 31% 1% 0% 2% 28% 1% DKK 135 DKK 300 DKK 96 DKK 78 DKK 497 million million million million million EBIT margin Special items Mesh provision EBIT margin Atos EBIT 9M Amortisation EBITA Depreciation EBITDA after
Slide 54: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2021/22 and hedging policy Revenue FX exposure 2021/22(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -420 USD -170 EUR 36% -290 CNY, JPY, AUD, BRL & ARS 13% GBP -200 HUF 0 120 14% GBP 19% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 55: US Mesh litigation - financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 Restricted cash, DKKbn YTD 0.5 0.5 EBIT (before special items) 4,147 4,535
Slide 56: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC Reimbursement pressure Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Car
Slide 57: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 58: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Coloplast Group - Ostomy Care / Cont
Slide 59: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance $ Product Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care Page 59
Slide 60: Interventional Urology revenue balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 12-13bn market FY 20/21 growing 3-5% annually 11% Coloplast position, FY 20/21 Endourology Men’s Health Women’s Health Bladder H
Slide 61: Interventional Urology four business areas and select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S BLADDER HEALTH & ENDOUROLOGY HEALTH HEALTH SURGERY • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 62: Strong presence in categories with room to capture share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 63: Coloplast acquires Nine Continents Medical
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 64: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn RoW Silic
Slide 65: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 66: In US Ostomy Care, innovation is biggest growth driver
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 67: Access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type 3,6
Slide 68: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products and packaging Reducing emissions Responsible operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products As a growing company, we are challenged Our people and cult
Slide 69: 9M 21/22 progress on key sustainability ambitions
9M 21/22 progress on key sustainability ambitions – carbon emission targets approved by the SBTi* in June 2022 Improving products and packaging Reducing emissions2 Responsible operations 2025 FY 9M 9M 2025 FY 9M 9M 2025 FY 9M 9M Ambition 20/21 21/22 20/21 Ambition 20/21 21/22 20/21 Ambition 20/21 21
Slide 70: Our 2025 priority: Reducing emissions
Our 2025 priority: Reducing emissions We are committed to reducing emissions while being a growth company Scope 3 - Other reported Scope 1 & 2 - Natural gas 2025 target – Scope 1+2 9% and company cars 13% Net-zero 100% Renewable energy (PPAs and phase out Scope 3 – Transportation natural gas use) of
Slide 71: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 72: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products • Market size of DKK ~3bn • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal Brava® Skin Barrier • Main competitors include: Hollister • Designed for leakage • Reducing skin problems Adapt, ConvaTec, 3M Ca
Slide 73: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia (BPH) & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management Speedi
Slide 74: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Peristeen® Plus Anal Irrigation Faecal incontinence Launched in 2021 + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many •
Slide 75: Introducing Interventional Urology
Introducing Interventional Urology Surgical treatment of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Custo
Slide 76: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues (WSC) Chronic wounds • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Customer groups Wound Care other Contract manufacturing & call points Hospitals Biatain® Silicone Non-Border B
Slide 77: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse® Bath Hospi
Slide 78: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK 4-5bn + CMS Value Based Purchasing with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 79: Introducing Voice & Respiratory Care - Laryngectomy
Introducing Voice & Respiratory Care – Laryngectomy Key products - Laryngectomy Distribution of revenues* Disease areas People that have undergone a total Provox® Life ™ Heat and Moisture Exchangers (HMEs) laryngectomy, a typical treatment for HMEs advanced laryngeal and Adhesives hypopharyngeal can
Slide 80: Introducing Voice & Respiratory Care - Tracheostomy
Introducing Voice & Respiratory Care – Tracheostomy Key products – Tracheostomy Portfolio expansion Disease areas • Performed when the airways are restricted, e.g., during an emergency when the airways are • Strengthened the tracheostomy blocked, or when a disease or product portfolio with the other
Slide 81: Coloplast organisation: Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Ostomy Care Continence Care & Skin Care Urology Respiratory Care Marketing Marke
Slide 82: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 197
Slide 83: Income statement
Income statement DKKm Q3 2020/21 Q3 2021/22 Change 9M 2020/21 9M 2021/22 Change Revenue 4,835 5,849 21% 14,326 16,520 15% Gross profit 3,335 4,048 21% 9,792 11,359 16% SG&A costs -1,585 -2,083 31% -4,580 -5,654 23% R&D costs -185 -222 20% -548 -649 18% Other operating income/expenses 27 18 -33% 41 4
Slide 84: Balance sheet
Balance sheet DKKm 30 Jun 2021 30 Jun 2022 Change Balance, total 15,458 35,185 128% Assets Non-current assets 8,631 26,482 207% Current assets 6,827 8,703 27% of which: Inventories 2,378 3,022 27% Trade receivables 3,142 3,837 22% Marketable securities, cash, and cash equivalents 675 854 27% 675 Equ
Slide 85: Cash flow
Cash flow DKKm 9M 2020/21 9M 2021/22 Change EBIT 4,505 4,661 3% Amortisation 105 174 66% Depreciation 496 497 0% Change in working capital -421 -1,161 176% Net interest payments -16 -202 nm Paid tax -1,413 -1,085 -23% Other 80 75 -6% Cash flow from operations 3,336 2,959 -11% Investment in intangibl
Slide 86: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 12% 0% Mørdrup Hörby China 2% Nieder-Olm Tatabánya Minneapolis Nyirbátor US/France Mankato Sarlat Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% 18% Salary - Direct 12% Salary - Indirect 7% Materials (RM &SFG) Innovation
Slide 87: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 88: Production sites
Production sites Denmark Germany Mørdrup Nieder-Olm • Pilot development work Ostomy care, • Specialised production Continence care and Wound care • Research & Development centre and • Adhesives production manufacturing of tracheostomy products • Number of employees in production: ~150 • Number of em
Slide 89: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 90: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Margrethe Borgbjerg Otto Munk Madsen Director, Investor Relations Senior Manager, Investor Relations Coordinator & PA, Investor Relations Student Assistant, Investor Relations Tel. direct: +45 491
Slide 91: Page 91
Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care Page 91